Sarcoma is a rare and deadly form of cancer occurring in the bones and connective tissue that affects people of all ages. Its aggressiveness, rarity and diversity continue to hinder efforts to identify effective therapies ...

A team from the Spanish National Cancer Research Centre (CNIO) has optimized a system capable of generating a cellular model of Ewing sarcoma. The technique, based on CRISPR and described in the pages of Stem Cell Reports, ...

Sarcomas—cancers of the connective tissues like muscles, joints, fat and bone—come in dozens of subtypes. Clinical trial results have been mixed when treating these diverse tumors with immunotherapy, a targeted therapeutic ...

The total number of cancer cases diagnosed among people living with the human immunodeficiency virus (HIV) is projected to decline in coming years, due mostly to declines in non-Hodgkin lymphoma and Kaposi sarcoma. Certain ...

By the time Ewing's Sarcoma is diagnosed, primarily in teens and young adults, it has often spread from its primary site to other parts of the body, making it difficult to treat. A University of Colorado Cancer Center study ...

The protein P-S6S240 may serve as an indicator of poor prognosis for patients with a hard-to-treat type of uterine sarcoma called leiomyosarcoma, and preclinical data suggest that patients whose tumors have this protein may ...

Patients with a type of advanced malignant cancer of the arms or legs have typically faced amputation of the afflicted limb as the only treatment option. However, a technique that limits the application of chemotherapy to ...

Tumors of the elderly, such as breast cancer and colon cancer, accumulate thousands of DNA mutations. These genetic defects contribute to cancer-specific properties including uncontrolled growth, invasion in neighboring tissues, ...

Munich, Germany: Researchers working to find effective treatments for soft tissue sarcomas have discovered that combining a new anti-cancer drug with an existing one kills cancer cells not only in the laboratory but also ...